


Supplementary Figure S2



Supplementary Figure S2. MEKi has modest anti-proliferative and pro-apoptotic effects on AC1 cells, but not SC1 cells. (A-B) PTEN/p53-deficient GEM tumor derived cancer cell lines AC1//SC1 cells were treated with copanlisib ($IC_{90} = 100$ nM), trametinib ($IC_{90} = 5$ nM) or their combination for 24, 48 and 72 hours. (A) Proliferation index was calculated by counting number of tumor cells in each well, relative to their baseline seeding density. (B) Tumor cells were stained for annexin V antibody/propidium iodide and % cell death was analyzed by flow cytometry. $n=3$ independent biological experiments. Significances/p-values were calculated by one-way ANOVA and indicated as follows, ** $p < 0.01$ and *** $p < 0.001$.